OssDsign Announces Planned Change of Chief Executive Officer

Report this content

OssDsign announces that Morten Henneveld will become Chief Executive Officer upon the retirement of Anders Lundqvist. 

Outgoing CEO Anders Lundqvist indicated to the Board earlier in the year that having reached the age of 65, he wished to retire from his role once an appropriate successor had been found. The search included multiple high-quality candidates from multiple geographies and following an exhaustive process Morten Henneveld, currently Senior Vice President, Business Transformation and Strategy and member of the Executive Leadership Team for GN Hearing,  a global leader in hearing aids, has been appointed to the role. He will take up his position on 1st September 2020. 

Chairman Simon Cartmell OBE commented: ‘Anders Lundqvist has overseen an extraordinary period of development for OssDsign. He led the private placement and IPO last year, has driven consecutive quarterly growth in line with our targets, has expanded our market presence with approvals and reimbursement in France and Japan in the past 12 months and has managed the planned transition from a master distributor to OssDsign USA Inc. He has delivered all we planned to do in 2019 and 2020 and is leaving with our thanks and best wishes for his retirement’.

In response, Lundqvist replied: ‘it has been my privilege to lead OssDsign these past 6 years and I am delighted to hand over the leadership to someone as well suited to the role as Morten Henneveld. The company under his direction is posed for exciting growth ahead and I wish him and the team at OssDsign all the best for the future’.

Newly appointed CEO Morten Henneveld has extensive international and medical device experience having worked as Director, Commercial Excellence for Coloplast during 2008-2012, including a period working in the USA, and then, based in Malmo, working as Managing Director, Sweden and Regional Vice President, Nordics for Biomet and subsequently Vice President, EMEA Spine for Zimmer Biomet from 2012-2016.  He said: ‘OssDsign has great technology and a substantial global sales presence. The company is well positioned for sustained growth and I look forward to using my orthopaedic and commercial experience, and together with the OssDsign organization, lead the delivery of our targets over the coming years’. 

For further information, please contact:
Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08
Email: al@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.